Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) has launched the SleepCheck smartphone app on select Android devices
- So far, it is only available on five Android devices, however, there is potential to add additional devices in the near term
- The app diagnoses the risk of sleep apnoea by analysing the user’s snoring and breathing during sleep
- Sleep apnoea occurs when air stops flowing to a person’s lungs for more than 10 seconds during sleep
- If untreated, it can cause stroke, heart disease, and type 2 diabetes
- After the Christmas break, shares in ResApp are up a slight 1.25 per cent, trading at 8.1 cents
ResApp Health (RAP) has launched the SleepCheck smartphone app on select Android devices.
It is now available on the App Store for iPhones and on Google Play for Androids.
So far, however, SleepCheck is only supported on the Samsung Galaxy S9, S9+, S10, S10+ and S20 devices, but there is potential to add more devices in the near term.
SleepCheck analyses a person’s breathing and snoring sounds during sleep and uses clinically accurate algorithms to assess their risk of obstructive sleep apnoea.
Similar to ResApp’s ResAppDx-EU device, which analyses a person’s cough sounds to diagnose disease, SleepCheck does not require any additional accessories or hardware — just a smartphone.
Further, it has achieved CE Mark in Europe and is Therapeutic Goods Administration (TGA) approved for the Australian Register of Therapeutic Goods (ARTG) listing in Australia as a class one medical device.
Sleep apnoea occurs when the air stops flowing to a person’s lungs for more than 10 seconds during sleep. If patients are left untreated, the condition can lead to heart disease, stroke, hypertension, and type 2 diabetes.
“The Android device market is large and well-established with over 2.5 billion devices globally and we are very pleased to have launched SleepCheck to cater for these users,” CEO and Managing Director Dr Tony Keating commented.
“The launched followed extensive internal testing to ensure that SleepCheck version 1.4 delivers a best-in-class experience and solution for people to accurately self-assess their risk of sleep apnoea,” he said.
“SleepCheck is a very unique offering with broad reach and availability and it has considerable potential in the sleep health space. We are excited about the ongoing opportunities it will present for ResApp,” he added.
After the Christmas break, shares in ResApp are up a slight 1.25 per cent, trading at 8.1 cents at 10:29 am AEDT.
